The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

  title={The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience},
  author={Timothy E. Albertson and John R. Richards and Amir A. Zeki},
  journal={Therapeutic Advances in Respiratory Disease},
  pages={43 - 56}
The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI… 

Tables from this paper

The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials
The results from the SLS, along with those of large and small RCTs, are supportive of the use of once-daily FF/VI in COPD maintenance therapy.
Pharmacotherapeutic management of asthma in the elderly patient
Inhaled, long-acting bronchodilators in combination with inhaled corticosteroids represent the backbone of treatment for the elderly patient with asthma or ACOS and a stepwise approach to escalation of therapy includes multiple options.
In Vitro Analysis of Nine MicroRNAs in CD8+ T Cells of Asthmatic Patients and the Effects of Two FDA-approved Drugs.
The correlation between miRNAs would be a very important factor in physiological and pathological conditions in healthy individuals and asthmatic patients and such a miRNA-miRNA correlation network can be even more critical than any changes in the variation of their expression in the CD8+ T cells.
Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma
The development of once daily ICS/LABA combinations may potentially improve adherence to asthma therapy, but this has yet to be demonstrated.


Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
Once-daily FF/VI reduced the risk of severe asthma exacerbations and improved lung function compared with FF alone, with good tolerability and safety profile in adolescents and adults with asthma currently receiving ICS.
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids
Based on the overall efficacy and adverse event profile from this study, the optimum dose of VI appears to be 25 μg, which resulted in prolonged bronchodilation of at least 24 h with good tolerability in asthma patients receiving ICS.
Fluticasone Furoate/Vilanterol: a Review of Its Use in Patients with Asthma
In clinical trials, fluticasone furoate/vilanterol was generally well tolerated with fewer than 15 % of patients experiencing treatment-related adverse events, the most common of which were oral/oropharyngeal candidiasis, dysphonia, extrasystoles and cough.
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Fluticasone furoate (FF)/vilanterol improved lung function and symptomatic end-points compared with FF alone and was well tolerated in this asthma population.
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
FF 200 μg OD in the evening is an efficacious and well tolerated treatment for asthma patients and is not inferior to the same total BD dose.
Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial
FF 100 alone and in combination with VI 25 provides significant bronchoprotection against the EAR in subjects with mild asthma, and this protection is provided at the trough of dosing supports the utility of FF 100 and FF/VI 100/25 as viable once-daily therapies.
Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study
Improvements from baseline in trough FEV1 were observed after 24 weeks of treatment with both doses of Fluticasone furoate, with a numerically greater improvement inFEV1 observed in patients receiving FF 200 μg.
Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma
The efficacy of once-daily FF/VI was similar to bid FP/SAL in improving lung function in patients with persistent asthma, and both treatments were well tolerated.